Cargando…

Phase 1b trial of anti-VEGF/PDGFR vorolanib combined with immune checkpoint inhibitors in patients with advanced solid tumors

PURPOSE: Vorolanib is a multi-target tyrosine kinase inhibitor with anti-angiogenic properties. This study aimed to evaluate the tolerability, safety and efficacy of vorolanib when added to checkpoint inhibitors (CPIs) in patients with advanced solid tumors. METHODS: We conducted a phase 1b study of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bagegni, Nusayba A., Park, Haeseong, Kraft, Katlyn, O-Toole, Maura, Gao, Feng, Waqar, Saiama N., Ratner, Lee, Morgensztern, Daniel, Devarakonda, Siddhartha, Amin, Manik, Baggstrom, Maria Q., Liang, Chris, Selvaggi, Giovanni, Wang-Gillam, Andrea
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8956523/ https://www.ncbi.nlm.nih.gov/pubmed/35247086 http://dx.doi.org/10.1007/s00280-022-04406-6

Ejemplares similares

A phase II study of everolimus in patients with advanced solid malignancies with TSC1, TSC2, NF1, NF2 or STK11 mutations
por: Devarakonda, Siddhartha, et al.
Publicado: (2021)

Vorolanib and everolimus: Lenvatinib and everolimus part deux, or something new?
por: Chehrazi-Raffle, Alexander, et al.
Publicado: (2020)

Vorolanib, an oral VEGFR/PDGFR dual tyrosine kinase inhibitor for treatment of patients with advanced solid tumors: An open-label, phase I dose escalation and dose expansion trial
por: Song, Yan, et al.
Publicado: (2021)

Exploring the Feasibility of Utilizing Limited Gene Panel Circulating Tumor DNA Clearance as a Biomarker in Patients With Locally Advanced Non-Small Cell Lung Cancer
por: Knapp, Brendan, et al.
Publicado: (2022)

Clinical outcomes with neoadjuvant versus adjuvant chemotherapy for triple negative breast cancer: A report from the National Cancer Database
por: Bagegni, Nusayba A., et al.
Publicado: (2019)

Targeted Treatment for High-Risk Early-Stage Triple-Negative Breast Cancer: Spotlight on Pembrolizumab
por: Bagegni, Nusayba A, et al.
Publicado: (2022)

Phase 1 trial of vorolanib (CM082) in combination with everolimus in patients with advanced clear-cell renal cell carcinoma
por: Sheng, Xinan, et al.
Publicado: (2020)

Vorolanib, a novel tyrosine receptor kinase receptor inhibitor with potent preclinical anti-angiogenic and anti-tumor activity
por: Liang, Chris, et al.
Publicado: (2022)

Phase I, First‐in‐Human, Dose‐Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Vorolanib in Patients with Advanced Solid Tumors
por: Bendell, Johanna C., et al.
Publicado: (2018)

Safety and tolerability of oral vorolanib for neovascular (wet) age-related macular degeneration: a phase I, open-label study
por: Gao, Yunxia, et al.
Publicado: (2023)

Impact of VEGF, VEGFR, PDGFR, HIF and ERCC1 gene polymorphisms on thymic malignancies outcome after thymectomy
por: Berardi, Rossana, et al.
Publicado: (2015)

Comprehensive Dissection of PDGF-PDGFR Signaling Pathways in PDGFR Genetically Defined Cells
por: Wu, Erxi, et al.
Publicado: (2008)

Management of Diarrhea in Patients with HER2-Positive Breast Cancer Treated with Neratinib: A Case Series and Summary of the Literature
por: Kruse, Megan L., et al.
Publicado: (2021)

PDGFRβ regulates craniofacial development through homodimers and functional heterodimers with PDGFRα
por: Fantauzzo, Katherine A., et al.
Publicado: (2016)

Pre-radiotherapy ctDNA liquid biopsy for risk stratification of oligometastatic non-small cell lung cancer
por: Semenkovich, Nicholas P., et al.
Publicado: (2023)

Pre-radiotherapy ctDNA liquid biopsy for risk stratification of oligometastatic non-small cell lung cancer
por: Semenkovich, Nicholas P., et al.
Publicado: (2023)

PDGFR‐β and kidney fibrosis
por: Ortiz, Alberto
Publicado: (2020)

Treatment with Imatinib in NSCLC is associated with decrease of phosphorylated PDGFR-β and VEGF expression, decrease in interstitial fluid pressure and improvement of oxygenation
por: Vlahovic, G, et al.
Publicado: (2006)

Transactivation of PDGFRβ by dopamine D4 receptor does not require PDGFRβ dimerization
por: Chi, Sum Shing, et al.
Publicado: (2010)

PDGFR in PDGF-BB/PDGFR Signaling Pathway Does Orchestrates Osteogenesis in a Temporal Manner
por: Wang, Fangqian, et al.
Publicado: (2023)

Is PDGFR an important target for E-3810?
por: Damia, Giovanna, et al.
Publicado: (2012)

Genomics of PDGFR-rearranged hypereosinophilic syndrome
por: Rheinbay, Esther, et al.
Publicado: (2023)

RRx-001 followed by platinum plus etoposide in patients with previously treated small-cell lung cancer
por: Morgensztern, Daniel, et al.
Publicado: (2019)

Untangling the evolutionary roots of lung cancer
por: Devarakonda, Siddhartha, et al.
Publicado: (2019)

Cambogin Is Preferentially Cytotoxic to Cells Expressing PDGFR
por: Tian, Ze, et al.
Publicado: (2011)

PDGF/PDGFR effects in osteosarcoma and the “add-on” strategy
por: Xu, Jie, et al.
Publicado: (2018)

Lycorine inhibits angiogenesis by docking to PDGFRα
por: Lv, Fei, et al.
Publicado: (2022)

Effect of metastatic site on survival in patients with neuroendocrine neoplasms (NENs). An analysis of SEER data from 2010 to 2014
por: Trikalinos, Nikolaos A., et al.
Publicado: (2020)

Dihydroartemisinin selectively inhibits PDGFRα-positive ovarian cancer growth and metastasis through inducing degradation of PDGFRα protein
por: Li, Xiaoguang, et al.
Publicado: (2017)

VEGF-A/VEGFR-2 and FGF-2/FGFR-1 but not PDGF-BB/PDGFR-β play important roles in promoting immature and inflammatory intraplaque angiogenesis
por: Mao, Yang, et al.
Publicado: (2018)

Gene expression-based screening for inhibitors of PDGFR signaling
por: Antipova, Alena A, et al.
Publicado: (2008)

ARF sees Pdgfrβ through the miR
por: Reed, Sara M, et al.
Publicado: (2014)

Telocytes express PDGFRα in the human gastrointestinal tract
por: Vannucchi, Maria-Giuliana, et al.
Publicado: (2013)

Dysregulated mesenchymal PDGFR‐β drives kidney fibrosis
por: Buhl, Eva M, et al.
Publicado: (2020)

Constitutive activation of oncogenic PDGFRα-mutant proteins occurring in GIST patients induces receptor mislocalisation and alters PDGFRα signalling characteristics
por: Bahlawane, Christelle, et al.
Publicado: (2015)

Nanopore sequencing for the screening of myeloid and lymphoid neoplasms with eosinophilia and rearrangement of PDGFRα, PDGFRβ, FGFR1 or PCM1-JAK2
por: Romagnoli, Simone, et al.
Publicado: (2021)

M2 Macrophages Promote PDGFRβ(+) Pericytes Migration After Spinal Cord Injury in Mice via PDGFB/PDGFRβ Pathway
por: Li, Ziyu, et al.
Publicado: (2021)

Targeting the PDGF-B/PDGFR-β Interface with Destruxin A5 to Selectively Block PDGF-BB/PDGFR-ββ Signaling and Attenuate Liver Fibrosis
por: Wang, Xingqi, et al.
Publicado: (2016)

Bone metastases in non-small cell lung cancer: a narrative review
por: Knapp, Brendan J., et al.
Publicado: (2022)

Blockade of PDGFR-β Activation Eliminates Morphine Analgesic Tolerance
por: Wang, Yan, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_rjj7kt1o5mn2mk0pglbnum90r1